JP2010515774A - 乾せんの治療方法 - Google Patents

乾せんの治療方法 Download PDF

Info

Publication number
JP2010515774A
JP2010515774A JP2009546413A JP2009546413A JP2010515774A JP 2010515774 A JP2010515774 A JP 2010515774A JP 2009546413 A JP2009546413 A JP 2009546413A JP 2009546413 A JP2009546413 A JP 2009546413A JP 2010515774 A JP2010515774 A JP 2010515774A
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding portion
subject
psoriasis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009546413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010515774A5 (enExample
Inventor
バルデス，ホアキン・マリオ
チヤータツシユ，エリオツト・キース
バーチユク，ウイリアム・テイー
ポールソン，スーザン・ケイ
キンボール，アレクサンドラ・ビー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of JP2010515774A publication Critical patent/JP2010515774A/ja
Publication of JP2010515774A5 publication Critical patent/JP2010515774A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2009546413A 2007-01-16 2008-01-16 乾せんの治療方法 Pending JP2010515774A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US88076707P 2007-01-16 2007-01-16
US90402207P 2007-02-27 2007-02-27
US92596007P 2007-04-24 2007-04-24
US96176407P 2007-07-24 2007-07-24
US99701207P 2007-09-28 2007-09-28
PCT/US2008/000564 WO2008088823A2 (en) 2007-01-16 2008-01-16 Methods for treating psoriasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015052928A Division JP2015145389A (ja) 2007-01-16 2015-03-17 乾せんの治療方法

Publications (2)

Publication Number Publication Date
JP2010515774A true JP2010515774A (ja) 2010-05-13
JP2010515774A5 JP2010515774A5 (enExample) 2011-04-07

Family

ID=39636572

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009546413A Pending JP2010515774A (ja) 2007-01-16 2008-01-16 乾せんの治療方法
JP2015052928A Pending JP2015145389A (ja) 2007-01-16 2015-03-17 乾せんの治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015052928A Pending JP2015145389A (ja) 2007-01-16 2015-03-17 乾せんの治療方法

Country Status (15)

Country Link
US (2) US7776331B1 (enExample)
EP (2) EP2117303A4 (enExample)
JP (2) JP2010515774A (enExample)
KR (2) KR20090100461A (enExample)
CN (1) CN104524567A (enExample)
AU (1) AU2008205512B2 (enExample)
BR (1) BRPI0806605A2 (enExample)
CA (1) CA2675233A1 (enExample)
HK (1) HK1203305A1 (enExample)
IL (1) IL199739A0 (enExample)
MX (1) MX2009007570A (enExample)
NZ (1) NZ578065A (enExample)
RU (2) RU2475265C2 (enExample)
SG (1) SG177982A1 (enExample)
WO (1) WO2008088823A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011515404A (ja) * 2008-03-18 2011-05-19 アボット・ラボラトリーズ 乾癬を治療するための方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
CN104524567A (zh) 2007-01-16 2015-04-22 阿布维公司 用于治疗银屑病的方法
KR20100014674A (ko) 2007-03-29 2010-02-10 아보트 러보러터리즈 결정성 항-사람 ｉｌ-12 항체
US20120225080A1 (en) * 2008-03-18 2012-09-06 Abbott Laboratories Human antibodies that bind the p40 subunit of human il-12/il-23 and uses therefor
EP2326668B1 (en) * 2008-08-14 2018-01-17 Teva Pharmaceuticals Australia Pty Ltd Anti-il-12/il-23 antibodies
CA2734919C (en) * 2008-08-27 2016-08-16 Schering Corporation Lyophilized formulations of engineered anti-il-23p19 antibodies
KR20140048229A (ko) * 2009-09-14 2014-04-23 애브비 인코포레이티드 건선을 치료하는 방법
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
US11643460B2 (en) * 2014-10-28 2023-05-09 Staley Brod Administration of an anti-interleukin 12/23 antibody for treatment of autoimmune disease
RU2562316C1 (ru) * 2014-12-10 2015-09-10 Сергей Владимирович Москвин Способ лазерной терапии больных псориазом

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002542770A (ja) * 1999-03-25 2002-12-17 クノール・ゲー・エム・ベー・ハー ヒトｉｌ−１２に結合するヒト抗体およびその産生法

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
KR0185192B1 (ko) 1989-10-05 1999-04-01 제임스 더블유. 데이비 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DE69133476T2 (de) * 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US7084260B1 (en) * 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
ATE204299T1 (de) * 1993-03-05 2001-09-15 Bayer Ag Humane monoklonale anti-tnf alpha antikörper
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5654168A (en) 1994-07-01 1997-08-05 Basf Aktiengesellschaft Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
CA2125763C (en) 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
EP0638644A1 (en) 1993-07-19 1995-02-15 F. Hoffmann-La Roche Ag Receptors of interleukin-12 and antibodies
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
WO1996012436A1 (en) * 1994-10-20 1996-05-02 Instent, Inc. Cystoscope delivery system
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
DK2275119T3 (da) 1995-07-27 2013-11-11 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US5853697A (en) 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US6297395B1 (en) * 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
WO1997029131A1 (en) 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
AU7257696A (en) 1996-10-11 1998-05-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12
ATE256476T1 (de) 1996-11-15 2004-01-15 Kennedy Inst Of Rheumatology Unterdrückung von tnfalpha und il-12 in der therapie
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
NZ337769A (en) 1997-03-18 2002-09-27 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
WO1999009055A2 (en) 1997-08-18 1999-02-25 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
AU744302B2 (en) 1997-10-31 2002-02-21 Beth Israel Deaconess Medical Center Use of anti-IL-12 antibodies in transplantation rejection
PT1049717E (pt) 1998-01-23 2007-05-31 Hoffmann La Roche Anticorpos contra a il-12 humana.
US20020161199A1 (en) * 1998-04-08 2002-10-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
DK1137766T3 (da) 1998-12-09 2006-01-30 Protein Design Labs Inc Anvendelse af IL-12-antistoffer til behandling af psoriasis
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
BR0013231A (pt) 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
NZ526720A (en) 2000-12-28 2007-11-30 Altus Pharmaceuticals Inc Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies
AU2002314825A1 (en) 2001-05-30 2002-12-09 Centocor, Inc. Anti-p40 immunoglobulin derived proteins, compositions, methods and uses
WO2002098445A1 (fr) * 2001-05-30 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preparation de proteines
CN1703233A (zh) * 2002-07-12 2005-11-30 米德列斯公司 防止蛋白氧化降解的方法和组合物
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US7608260B2 (en) * 2003-01-06 2009-10-27 Medimmune, Llc Stabilized immunoglobulins
JP4764818B2 (ja) 2003-04-11 2011-09-07 メディミューン，エルエルシー 組換えｉｌ−９抗体およびその使用
AU2004239288B2 (en) * 2003-05-09 2010-01-28 Centocor, Inc. IL-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
JP4219932B2 (ja) * 2003-10-01 2009-02-04 協和発酵キリン株式会社 抗体の安定化方法及び安定化された溶液状抗体製剤
EP1694317A4 (en) * 2003-12-19 2010-05-12 Protemix Corp Ltd COPPER ANTAGONIST COMPOUNDS
HRP20120376T1 (hr) 2003-12-23 2012-05-31 Genentech Nova protutijela protiv il-13 i njihove upotrebe
KR20120089307A (ko) * 2004-02-12 2012-08-09 메르크 파텐트 게엠베하 항－ｅｇｆｒ 항체들의 고농축 액체 제형물
RU2292215C2 (ru) 2004-05-21 2007-01-27 Дмитрий Васильевич Николенко Комплекс для лечения псориаза и способ лечения
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
ES2531155T3 (es) 2004-07-23 2015-03-11 Genentech Inc Cristalización de anticuerpos anti-VEGF
NZ555658A (en) 2004-12-21 2010-04-30 Centocor Inc Anti-IL-12 antibodies, epitopes, compositions, methods and uses
EP3501537A1 (en) 2005-06-30 2019-06-26 Janssen Biotech, Inc. Anti-il23 antibodies, compositions, methods and uses
AU2007212147A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
EP2639319B1 (en) * 2006-09-11 2015-07-08 Celera Corporation Genetic polymorphisms associated with Psoriasis, methods of detection and uses thereof
CA2673533A1 (en) 2006-10-13 2008-04-17 Centocor Ortho Biotech Inc. Enhancement of hybridoma fusion efficiencies through cell synchronization
CN104524567A (zh) 2007-01-16 2015-04-22 阿布维公司 用于治疗银屑病的方法
KR20100014674A (ko) * 2007-03-29 2010-02-10 아보트 러보러터리즈 결정성 항-사람 ｉｌ-12 항체
US20120225080A1 (en) * 2008-03-18 2012-09-06 Abbott Laboratories Human antibodies that bind the p40 subunit of human il-12/il-23 and uses therefor
JP2011515404A (ja) * 2008-03-18 2011-05-19 アボット・ラボラトリーズ 乾癬を治療するための方法
EP2145898A1 (en) * 2008-07-15 2010-01-20 CHIESI FARMACEUTICI S.p.A. Anti-amyloid immunogenic compositions, methods and uses
AU2009319856A1 (en) * 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
KR20140048229A (ko) * 2009-09-14 2014-04-23 애브비 인코포레이티드 건선을 치료하는 방법
SG189836A1 (en) * 2010-10-06 2013-06-28 Abbvie Inc Methods for treating psoriasis
MX2013007904A (es) * 2011-01-07 2013-08-29 Abbvie Inc Anticuerpos anti-il-12/il-23 y usos de los mismos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002542770A (ja) * 1999-03-25 2002-12-17 クノール・ゲー・エム・ベー・ハー ヒトｉｌ−１２に結合するヒト抗体およびその産生法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6012063645; Ｊ．Ｉｎｖｅｓｔ．Ｄｅｒｍａｔｏｌ．，　２００４，　Ｖｏｌ．　１２３，　Ｎｏ．　６，　Ｐ．　１０３７-１０４４ *
JPN6013040367; Ｊ．ＩＮＶＥＳＴ．ＤＥＲＭＡＴＯＬ． ＶＯＬ．１２５，　ＮＯ．３，　ＳＵＰＰＬ．Ｓ, 2005, Ｐ．Ａ６９ *
JPN6014015672; Ｎ．ＥＮＧ．Ｊ．ＭＥＤ． ＶＯＬ．３５１，　ＮＯ．２０, 2004, Ｐ．２０６９-２０７９ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011515404A (ja) * 2008-03-18 2011-05-19 アボット・ラボラトリーズ 乾癬を治療するための方法

Also Published As

Publication number Publication date
EP2117303A4 (en) 2011-06-08
KR20090100461A (ko) 2009-09-23
CA2675233A1 (en) 2008-07-24
WO2008088823A2 (en) 2008-07-24
AU2008205512B2 (en) 2014-06-12
US7776331B1 (en) 2010-08-17
EP2117303A2 (en) 2009-11-18
RU2475265C2 (ru) 2013-02-20
JP2015145389A (ja) 2015-08-13
RU2012147583A (ru) 2014-05-20
SG177982A1 (en) 2012-02-28
RU2009131080A (ru) 2011-02-27
US9051368B2 (en) 2015-06-09
EP2839743A1 (en) 2015-02-25
NZ578065A (en) 2012-09-28
WO2008088823A3 (en) 2008-11-20
CN104524567A (zh) 2015-04-22
IL199739A0 (en) 2010-04-15
HK1203305A1 (en) 2015-10-30
BRPI0806605A2 (pt) 2011-09-06
US20100297143A1 (en) 2010-11-25
AU2008205512A1 (en) 2008-07-24
MX2009007570A (es) 2009-07-22
KR20150038227A (ko) 2015-04-08

Similar Documents

Publication Publication Date Title
JP4841038B2 (ja) ヒトｉｌ−１２に結合するヒト抗体およびその産生法
TWI461210B (zh) 治療牛皮癬的方法
JP2015145389A (ja) 乾せんの治療方法
JP2010513529A (ja) ヒトｉｌ−１２を結合するヒト抗体及び製造方法
KR20120112384A (ko) 건선을 치료하는 방법
AU2013202849A1 (en) Methods for treating psoriasis
CN101636080A (zh) 用于治疗银屑病的方法
HK1142083B (en) Human antibodies that bind human il-12 and methods for producing
HK1156958A (en) Human antibodies that bind human il-12 and methods for producing

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110218

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20121029

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20121129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130306

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130528

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20130701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140710

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141015

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141118